OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO

Published June 2, 2012

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO

Filed under: San Antonio Drug Rehab Centers

The study results were presented by Dr. Anthony Tolcher of The START Center for Cancer Care, San Antonio, TX. Dr. Tolcher noted that the main treatment-related adverse event was diarrhea and there was evidence of Notch pathway modulation with this drug …
Read more on MarketWatch (press release)

GenSpera Appoints Dr. Peter E. Grebow to Its Board of Directors

Filed under: San Antonio Drug Rehab Centers

SAN ANTONIO–(BUSINESS WIRE)–May 31, 2012 – GenSpera, Inc. (OTCBB:GNSZ) announced the appointment of Peter E. Grebow, Ph.D. to its Board of Directors. Dr. Grebow will be the company's third independent director and will serve on the company's (i) …
Read more on PharmaLive.com (press release)

GenSpera Appoints Dr. Peter E. Grebow to Its Board of Directors

Filed under: San Antonio Drug Rehab Centers

SAN ANTONIO–(EON: Enhanced Online News)–GenSpera, Inc. (OTCBB:GNSZ) announced the appointment of Peter E. Grebow, Ph.D. to its Board of Directors. Dr. Grebow will be the company's third independent director and will serve on the company's (i) Audit …
Read more on EON: Enhanced Online News (press release)

More San Antonio Drug Rehab Centers Resources

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Access Content

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO of Michigan Cancer Center at Ann Arbor, MI also participated in the Phase I study. The anti-Notch2/3 program is part of OncoMed … Retrieve Full Source

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Document Viewer

OncoMed Presents First-in-Human Phase I Data On Anti-Notch2/3 Antibody At ASCO
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL. … Read News

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Get Content Here

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Access Full Source

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … View Doc

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO Business Wire CHICAGO — June 02, 2012 OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells … Access Document

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
Press release. June 2, 2012, 2:15 p.m. EDT OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Document Retrieval

OncoMed Presents First-in-Human Phase I Data On Anti-Notch2/3 Antibody At ASCO
CHICAGO–(BUSINESS WIRE)–OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL. This represents the first … Read News

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
NEXT ARTICLE OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Read Here

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
Latest Technology News OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Access This Document

OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 …
OncoMed Presents First-in-Human Phase I Data on Anti-Notch2/3 Antibody at ASCO … Doc Retrieval